Absci appoints Mary Szela to Board of Directors, brings decades of biopharma experience.

Absci, a clinical-stage biopharmaceutical company, has appointed Mary Szela to its Board of Directors. Szela has decades of R&D and commercial leadership experience, including guiding the global launch of Humira. She joins Absci as the company accelerates its potentially category-defining programs, such as ABS-201 for androgenetic alopecia. Szela's experience will help Absci advance breakthrough therapeutics designed with generative AI.

Clinical-stage biopharmaceutical company Absci (NASDAQ: ABSI) has appointed Mary Szela to its Board of Directors. Szela, currently CEO of TriSalus Life Sciences, brings over three decades of experience in biopharmaceutical research and development, as well as commercial leadership. Notably, she guided the global launch of Humira® at Abbott Laboratories.

Szela joins Absci at a pivotal moment as the company advances its AI-designed biologics pipeline. The pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease (IBD) with Phase 1 data expected in 2025, and ABS-201 for androgenetic alopecia planned for clinical trials in early 2026. Her extensive board experience includes roles at Prometheus Biosciences, Kura Oncology, and Novo Nordisk.

Absci's strategic focus on AI-designed biologics underscores the company's commitment to innovation. The appointment of Szela, with her proven track record in R&D and commercial leadership, positions Absci to accelerate its potentially category-defining programs. Szela's expertise will be crucial in advancing breakthrough therapeutics designed with generative AI.

[1] https://www.stocktitan.net/news/ABSI/absci-appoints-biopharma-leader-mary-szela-to-board-of-xdrgrmilsqkr.html

[2] https://finance.yahoo.com/news/everest-medicines-showcases-breakthroughs-proprietary-085800917.html